Axol Biosciences offers new screening assay for hiPSC-derived cells

By The Science Advisory Board staff writers

October 13, 2020 -- Axol Biosciences has added multielectrode array (MEA) screening services for human-induced pluripotent stem cell (hiPSC)-derived cells to its service offering for preclinical drug discovery.

The company said that its new MEA screening services optimize hiPSC-derived cell culture, while also providing electrophysiology acquisition and analysis from physiologically relevant human cell models.

The expansion combines Axol's hiPSC-derived human cells and electrophysiological experience with Axion Biosystems' Maestro Pro MEA platform, according to the firm. The Maestro Pro supports continuous label-free and real-time data acquisition and analysis from 768 electrodes in up to a 96 wp format, Axol said.

Curi Bio launches ComboMat to aid preclinical drug development
Curi Bio released its new proprietary ComboMat platform, a human induced pluripotent stem cell cardiomyocyte maturation technology with applications in...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter